SermorelinAlso known as: GRF 1-29, GHRH 1-29

Mechanism of Action

Sermorelin is a synthetic analogue of the first 29 amino acids of endogenous GHRH. It stimulates the pituitary gland to produce and secrete growth hormone naturally.

Reported Research Benefits

Hormonal optimization, anti-aging, improved body composition, sleep quality, libido.

Dosing Protocol & Reconstitution

Typically administered at 0.2–0.3 mg subcutaneously before bed. Long-term use (3–6 months) is common for hormonal optimization goals.

Research Notes

FDA-approved for GH deficiency in children; widely used off-label in adults for anti-aging. Preserves pituitary function better than exogenous GH.

Research Summary

Sermorelin is the 29-amino-acid N-terminal fragment of endogenous GHRH, the first FDA-approved growth hormone secretagogue for pediatric GH deficiency. It stimulates pulsatile, physiological GH release from the pituitary and has been studied in adults for anti-aging and body composition. It preserves the natural GH feedback loop, reducing pituitary suppression risk compared to exogenous GH.

Side Effects & Safety

Generally well-tolerated. Injection site redness or swelling is most common. Flushing, headache, dizziness, and nausea reported. Peripheral edema and joint pain at higher doses. Unlike exogenous GH, suppression of the HPG axis is not expected due to preserved feedback control.

Stability & Storage

Refer to research notes

Molecular Data

Sequence: Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH2
Molecular Formula: C149H246N44O42S
Molecular Weight: 3357.93 g/mol
CAS Number: 86168-78-7

Primary literature: https://pubmed.ncbi.nlm.nih.gov/?term=Sermorelin+GHRH+growth+hormone+deficiency